Skip to main content
. 2016 Feb 15;25(1):93–98. doi: 10.1016/j.jsps.2016.02.002

Table 1.

Baseline characteristics.

Dabigatran (n = 65) Rivaroxaban (n = 34) Apixaban (n = 14)
Mean ± SD age, yr 71 ± 11 70 ± 15 70 ± 14



Gender, n
 Male 28 16 6
 Female 37 18 8



Indication, n
 Stroke prevention 64 21 9
 VTE prophylaxis/treatment 1 13 5



Status of NOACs, n
 Home medication 51 18 4
 New start 14 16 10



Cancer, n 2 4 1



Concurrent use of antiplatelets, n
 Aspirin 325 mg 3 0 0
 Aspirin 81 mg 18 9 4
 Clopidogrel 75 mg 1 1 1

VTE = venous thromboembolism, NOACs = novel oral anticoagulants.